Clinical Trial Update: Study of Efficacy and Safety LMF237 in Patients With Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled With Vildagliptin Monotherapy [Phase 3]

View source ↗

Summary

Phase 3 study assessing the efficacy and safety of LMF237 in adults with Type 2 diabetes inadequately controlled on vildagliptin monotherapy; results from the c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• LMF237
• Vildagliptin (vildagliptin)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Diabetes Mellitus, Type 2 | Phase 3 | Status: COMPLETED | Results posted: 2015-02-23